AnalystsArlinda LeeArlinda Lee's Stock Forecasts
AnalystsArlinda Lee
Analyst Ranking
Bottom 6%
#4601 out of 4870 analysts
Average Return
-7.81%
Win Rate
44%15 out of 34
Risk vs Reward
Poor
Good
Arlinda Lee's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Rhythm Pharmaceuticals IncRYTM | +130.01% | $9.53 | $21.92 | 2022-03-07 - 2023-03-06 | Strong Buy |
Delcath Systems IncDCTH | +110.22% | $4.60 | $9.67 | 2023-09-07 - 2024-09-06 | Strong Buy |
Akari Therapeutics PLCAKTX | +96.70% | $36.40 | $71.60 | 2018-03-29 - 2019-03-29 | Strong Buy |
Zynerba Pharmaceuticals IncZYNE | +81.75% | $5.59 | $10.16 | 2018-08-03 - 2019-08-02 | Strong Buy |
Neurogene IncNGNE | +58.57% | $150.60 | $238.80 | 2020-03-12 - 2021-03-12 | Strong Buy |
Arlinda Lee Analyst Color
Get additional color on Arlinda Lee's coverage of popular stocks
Arlinda Lee's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Delcath Systems IncDCTH | 3 | Strong Buy | $21.00 | N/A | Maintains | 2 years ago |
X4 Pharmaceuticals IncXFOR | 3 | Strong Buy | $300.00 | N/A | Maintains | 3 years ago |
Harpoon Therapeutics IncHARP | 1 | Strong Buy | $140.00 | N/A | Maintains | 3 years ago |
Nektar TherapeuticsNKTR | 4 | Strong Buy | $6.00 | N/A | Maintains | 3 years ago |
Rhythm Pharmaceuticals IncRYTM | 1 | Strong Buy | $36.00 | N/A | Maintains | 3 years ago |
Deciphera Pharmaceuticals IncDCPH | 1 | Hold | $12.00 | N/A | Downgrades | 3 years ago |
Celcuity IncCELC | 1 | Strong Buy | $50.00 | N/A | Initiates Coverage On | 4 years ago |
Crispr Therapeutics AgCRSP | 1 | Strong Buy | $160.00 | N/A | Maintains | 4 years ago |
Bicycle Therapeutics PLCBCYC | 1 | Strong Buy | $36.00 | N/A | Maintains | 4 years ago |
Turning Point Therapeutics IncTPTX | 1 | Strong Buy | $145.00 | N/A | Maintains | 4 years ago |
Ultragenyx Pharmaceutical IncRARE | 3 | Strong Buy | $91.00 | N/A | Maintains | 5 years ago |
Neurogene IncNGNE | 1 | Strong Buy | $100.00 | N/A | Initiates Coverage On | 5 years ago |
Forty Seven IncFTSV | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Black Diamond Therapeutics IncBDTX | 1 | Strong Buy | $50.00 | N/A | Initiates Coverage On | 5 years ago |
Karyopharm Therapeutics IncKPTI | 3 | Strong Buy | $270.00 | N/A | Maintains | 5 years ago |
Zynerba Pharmaceuticals IncZYNE | 4 | Strong Buy | $18.00 | N/A | Assumes | 6 years ago |
Tvardi Therapeutics IncTVRD | 2 | Strong Buy | $288.00 | N/A | Maintains | 7 years ago |
Akari Therapeutics PLCAKTX | 1 | Strong Buy | $160.00 | N/A | Maintains | 7 years ago |
Tyme Technologies IncTYME | 1 | Strong Buy | $10.00 | N/A | Initiates Coverage On | 7 years ago |
Halozyme Therapeutics IncHALO | 1 | Strong Buy | $19.00 | N/A | Maintains | 7 years ago |
Blueprint Medicines CorpBPMC | 1 | Strong Buy | $66.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.